EP Patent

EP0633023A2 — Preventing emesis and treating sexual dysfunction using tetrahydrobenz CD indole-6-carboxamides

Assigned to Eli Lilly and Co · Expires 1995-01-11 · 31y expired

What this patent protects

The present invention provides methods of preventing emesis and treating sexual dysfunction in mammals utilizing certain tetrahydrobenz[cd]indoles. The invention further provides pharmaceutical formulations suitable for use in such methods.

USPTO Abstract

The present invention provides methods of preventing emesis and treating sexual dysfunction in mammals utilizing certain tetrahydrobenz[cd]indoles. The invention further provides pharmaceutical formulations suitable for use in such methods.

Drugs covered by this patent

solriamfetol-hydrochloride (SOLRIAMFETOL HYDROCHLORIDE)

Patent Metadata

Patent number: EP0633023A2
Jurisdiction: EP
Classification: —
Expires: 1995-01-11
Drug substance claim: No
Drug product claim: No
Assignee: Eli Lilly and Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.